Studies on Antiulcer Agents. I. Synthesis and Pharmacological Properties of Ethyl 2-((1H-Benzimidazol-2-yl)sulfinylmethyl)-4-dimethylamino-5-pyrimidinecarboxylate, a New H+/K+-ATPase Inhibitor Possessing Mucosal Protective Activity.
Studies on Antiulcer Agents. I. Synthesis and Pharmacological Properties of Ethyl 2-((1H-Benzimidazol-2-yl)sulfinylmethyl)-4-dimethylamino-5-pyrimidinecarboxylate, a New H+/K+-ATPase Inhibitor Possessing Mucosal Protective Activity.
Studies on Antiulcer Agents. I. Synthesis and Pharmacological Properties of Ethyl 2-((1H-Benzimidazol-2-yl)sulfinylmethyl)-4-dimethylamino-5-pyrimidinecarboxylate, a New H+/K+-ATPase Inhibitor Possessing Mucosal Protective Activity.
作者:Kohji TERASHIMA、Hiroshi SHIMAMURA、Akito KAWASE、Yuji TANAKA、Keiji UENISHI、Isami KIMURA、Yasuhiro ISHIZUKA、Makoto SATO
DOI:10.1248/cpb.43.166
日期:——
Ethyl 2-[(1H-benzimidazol-2-yl)sulfinylmethyl]-4-dimethylamino-5-pyrimidinecarboxylate (2) has been synthesized and evaluated for antiulcer properties. Compound 2 is a H+/K+-ATPase inhibitor that affords mucosal protection against absolute ethanol-induced gastric lesions in rats after oral and parenteral administrations. On the other hand, omeprazole, a representative H+/K+-ATPase inhibitor, showed mucosal protective action only after oral administration, indicating that it required gastric acid secretion to generate activity. The antiulcer activity of 2 in animal models, such as water-immersion stress-induced gastric ulcer in rats and acidified aspirin-induced gastric ulcer in rats, was three times higher than that of cimetidine.